Industry committee  I was only going to add that I think it is because clause 2 of Bill C-393 states, “Section 21.02 of the Act is replaced by the following”, and there are two definitions after that. One is for “authorization” and one is for “pharmaceutical product”. So the understanding was that w

Industry committee  I will just add that the intent.... When CAMR was first developed, when this legislation was first put in place, we were one of the first countries to do such legislation. We were developing the legislation without much precedent, so what was paramount was the interest in making

Industry committee  Clause 2 as it was put forward in Bill C-393 would have deleted the reference to schedule 1 and would have expanded the scope of eligible products for export under Canada's access to medicines regime to any drug as defined under section 2 of the Food and Drugs Act. That would hav

Industry committee  Bill C-393 proposed, as Mr. Marc Garneau said, to remove schedule 1, which is a list of drugs that was contained in CAMR, the drugs that were eligible for manufacture and export under the regime. It also contained three lists of countries--so schedules 2 to 4. The countries tha

Industry committee  That's right. It would be—

Industry committee  —one schedule of countries only, removed--

Industry committee  That is correct.

Industry committee  That is correct, and the amendment, as I understand it, would refer to clauses 2 to 4.

Industry committee  My understanding is that, as Mr. Garneau mentioned, it would reinsert schedule 1 into Canada's access to medicines regime, along with potentially another amendment, which I suppose we'll discuss later. But it's not clear to me how the other schedules, the country schedules, would